Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Sci Rep ; 14(1): 15810, 2024 07 09.
Article in English | MEDLINE | ID: mdl-38982132

ABSTRACT

Multisystemic inflammatory syndrome in children (MIS-C) might manifest in a broad spectrum of clinical scenarios, ranging from mild features to multi-organ dysfunction and mortality. However, this novel entity has a heterogenicity of data regarding prognostic factors associated with severe outcomes. The present study aimed to identify independent predictors for severity by using multivariate regression models. A total of 391 patients (255 boys and 136 girls) were admitted to Vietnam National Children's Hospital from January 2022 to June 2023. The median age was 85 (range: 2-188) months, and only 12 (3.1%) patients had comorbidities. 161 (41.2%) patients required PICU admission, and the median PICU LOS was 4 (2-7) days. We observed independent factors related to PICU admission, including CRP ≥ 50 (mg/L) (OR 2.52, 95% CI 1.39-4.56, p = 0.002), albumin ≤ 30 (g/L) (OR 3.18, 95% CI 1.63-6.02, p = 0.001), absolute lymphocyte count ≤ 2 (× 109/L) (OR 2.18, 95% CI 1.29-3.71, p = 0.004), ferritin ≥ 300 (ng/mL) (OR 2.35, 95% CI 1.38-4.01), p = 0.002), and LVEF < 60 (%) (OR 2.48, 95% CI 1.28-4.78, p = 0.007). Shock developed in 140 (35.8%) patients, especially for those decreased absolute lymphocyte ≤ 2 (× 109/L) (OR 2.48, 95% CI 1.10-5.61, p = 0.029), albumin ≤ 30 (g/L) (OR 2.53, 95% CI 1.22-5.24, p = 0.013), or LVEF < 60 (%) (OR 2.24, 95% CI 1.12-4.51, p = 0.022). In conclusion, our study emphasized that absolute lymphocyte count, serum albumin, CRP, and LVEF were independent predictors for MIS-C severity. Further well-designed investigations are required to validate their efficacy in predicting MIS-C severe cases, especially compared to other parameters. As MIS-C is a new entity and severe courses may progress aggressively, identifying high-risk patients optimizes clinicians' follow-up and management to improve disease outcomes.


Subject(s)
COVID-19 , Severity of Illness Index , Systemic Inflammatory Response Syndrome , Humans , Male , Female , Child , COVID-19/epidemiology , COVID-19/diagnosis , COVID-19/complications , Systemic Inflammatory Response Syndrome/diagnosis , Systemic Inflammatory Response Syndrome/epidemiology , Vietnam/epidemiology , Child, Preschool , Adolescent , Infant , SARS-CoV-2/isolation & purification , Prognosis , Lymphocyte Count , Intensive Care Units, Pediatric , C-Reactive Protein/analysis , C-Reactive Protein/metabolism
2.
J Anesth ; 35(5): 638-645, 2021 10.
Article in English | MEDLINE | ID: mdl-34259911

ABSTRACT

PURPOSE: Recombinant human soluble thrombomodulin (rTM) has been used to treat disseminated intravascular coagulation (DIC). Recent studies have shown the efficacy of rTM through its anti-inflammatory effects for treatment of adults with acute respiratory distress syndrome (ARDS). However, the safety and efficacy of rTM in children with severe ARDS complicated by DIC have not been reported. In this preliminary study, we reported the feasibility of using rTM for the treatment of pneumonia-induced severe ARDS complicated by DIC in children. METHODS: Six children (age: median 10 months old) with pneumonia-induced severe ARDS complicated by DIC were enrolled in this preliminary study. rTM (380 U/kg) was administered for a maximum of 6 days, in addition to conventional therapies after diagnosis of severe ARDS complicated by DIC. After administration of rTM, we measured changes in the plasma TM concentration and evaluated the clinical course, status of DIC and ARDS, and other laboratory findings, including levels of cytokines, chemokines, and biomarkers. RESULTS: In all six children, the plasma concentration of TM increased and DIC scores decreased after administration of rTM. Four of the six children recovered from the severe ARDS complicated by DIC after treatment, and were discharged from the hospital with no complications. In survived children, levels of soluble receptors for advanced glycation end products, interleukin-6, interleukin-8 and monocyte chemotactic protein-1 decreased after administration of rTM compared to those before rTM. CONCLUSIONS: The rTM administration is feasible as an adjunctive therapeutic strategy for children over 2 months with pneumonia-induced severe ARDS complicated by DIC.


Subject(s)
Disseminated Intravascular Coagulation , Pneumonia , Respiratory Distress Syndrome , Adult , Child , Disseminated Intravascular Coagulation/drug therapy , Disseminated Intravascular Coagulation/etiology , Humans , Infant , Pneumonia/complications , Pneumonia/drug therapy , Recombinant Proteins , Respiratory Distress Syndrome/drug therapy , Respiratory Distress Syndrome/etiology , Retrospective Studies , Thrombomodulin , Treatment Outcome
3.
Sci Rep ; 10(1): 159, 2020 01 13.
Article in English | MEDLINE | ID: mdl-31932599

ABSTRACT

Enterovirus-A71 (EV-A71) is a common cause of hand-foot-and-mouth disease (HFMD) and, rarely, causes severe neurological disease. This study aimed to elucidate the epidemiological and genetic characteristics and virulence of EV-A71 strains isolated from children diagnosed with HFMD. Rectal and throat swabs were collected from 488 children with HFMD in Hanoi, Vietnam, in 2015-2016. From 391 EV-positive patients, 15 EVs, including coxsackievirus A6 (CV-A6; 47.1%) and EV-A71 (32.5%, n = 127), were identified. Of the 127 EV-A71 strains, 117 (92.1%) were the B5 subgenotype and 10 (7.9%) were the C4 subgenotype. A whole-genome analysis of EV-A71 strains showed that seven of the eight C4a strains isolated in 2016 formed a new lineage, including two possible recombinants between EV-A71 C4 and CV-A8. The proportion of inpatients among C4-infected children was higher than among B5-infected children (80.0% vs. 27.4%; P = 0.002). The virulence of EV-A71 strains was examined in human scavenger receptor class B2 (hSCARB2)-transgenic mice, and EV-A71 C4 strains exhibited higher mortality than B5 strains (80.0% vs. 30.0%, P = 0.0001). Thus, a new EV-A71 C4a-lineage, including two possible recombinants between EV-A71 C4 and CV-A8, appeared in 2016 in Vietnam. The EV-A71 C4 subgenotype may be more virulent than the B5 subgenotype.


Subject(s)
Enterovirus/classification , Enterovirus/isolation & purification , Hand, Foot and Mouth Disease/epidemiology , Hand, Foot and Mouth Disease/mortality , Lysosomal Membrane Proteins/physiology , Receptors, Scavenger/physiology , Virus Replication , Animals , Child , Child, Preschool , Disease Outbreaks , Enterovirus/genetics , Female , Hand, Foot and Mouth Disease/virology , Humans , Infant , Male , Mice , Mice, Transgenic , Phylogeny , Serogroup , Survival Rate , Time Factors , Vietnam/epidemiology
4.
Chemosphere ; 241: 125068, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31629244

ABSTRACT

This paper reports a novel nanocomposite additive for a polyvinylidene fluoride (PVDF) membrane with high hydrophilicity through the association of graphene oxide (GO) and ZnO. The influence of the hydrophilicity of GO-ZnO on the PVDF membrane was examined on different GO-ZnO loadings. The porosity and wettability (or hydrophilicity) of the membrane were improved significantly by blending GO-ZnO nanocomposite. In addition, the water flux of the GO-ZnO/PVDF membrane was 48% higher than that of bare PVDF, and the anti-fouling properties of this modified membrane were also improved. The irreversible fouling ratio (Rir) of bovine serum albumin (BSA) was reduced substantially with increasing the loading of GO-ZnO nanocomposite. The lowest irreversible fouling ratio (7.21%) was obtained for the membrane containing 0.2 wt % GO-ZnO of the nanocomposite (M6). GO-ZnO modification PVDF membranes were assumed to reduce the affinity between membrane and BSA foulant, which improved the anti-fouling properties PVDF membrane. In the activated sludge flux test, the membrane containing GO-ZnO in the polymer matrix had a higher flux than that of the bare PVDF membrane. The effluent quality after the composite membrane (0.6 NTU) was stable, indicating that the composite membrane can be used for practical applications Overall, the properties of the PVDF membrane were improved after modification due to hydrogen bonding or the hydrophilicity of the GO-ZnO nanocomposite.


Subject(s)
Graphite/chemistry , Polyvinyls/chemistry , Ultrafiltration , Waste Disposal, Fluid/methods , Hydrophobic and Hydrophilic Interactions , Membranes, Artificial , Nanocomposites , Nanoparticles/chemistry , Polymers , Porosity , Serum Albumin, Bovine , Zinc Oxide/chemistry
5.
Pediatr Pulmonol ; 52(11): 1469-1477, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28703486

ABSTRACT

BACKGROUND: Acute respiratory distress syndrome (ARDS) is one of the most lethal diseases encountered in the pediatric intensive care unit (PICU). The etiological pathogens and prognostic factors of severe ARDS of pulmonary origin in children with respiratory virus infections were prospectively investigated. METHODS: Enrolled children fulfilled the following criteria: (1) PICU admission; (2) age of 1 month to 16 years; (3) diagnosis of infectious pneumonia and respiratory virus infection; and (4) development of severe ARDS within 72 h after PICU admission. Pathogens were detected in the blood and tracheal lavage fluid using molecular techniques and a conventional culture system. The serum levels of inflammatory mediators on the day of PICU admission were examined. RESULTS: Fifty-seven patients (32 boys; median age, 9 months) were enrolled. Multiple virus infections, co-infection with bacteria/fungus, and bacteremia/fungemia were observed in 60%, 49%, and 32% of children, respectively. Adenovirus-B, measles virus, and cytomegalovirus were detected predominantly in tracheal lavage fluid. There were no statistically significant differences between non-survivors and survivors regarding the types of pathogen, incidence of multiple virus infection, gender, age, clinical features, and treatment. The serum levels of interferon (IFN)-γ and the IFN-γ/interleukin (IL)-10 ratio were higher in non-survivors. CONCLUSIONS: IFN-γ upregulation as detected on the day of PICU admission was found to be one of the possible prognostic factors affecting a fatal outcome. These results suggest that modulation of inflammatory responses is critical for the clinical management of children with ARDS.


Subject(s)
Cytokines/immunology , Respiratory Distress Syndrome/microbiology , Bacterial Infections/blood , Bacterial Infections/immunology , Bacterial Infections/microbiology , Child , Child, Preschool , Coinfection/blood , Coinfection/immunology , Coinfection/microbiology , Cytokines/blood , Female , Hospitalization , Humans , Infant , Intensive Care Units, Pediatric , Lung/microbiology , Male , Mycoses/blood , Mycoses/immunology , Mycoses/microbiology , Prognosis , Respiratory Distress Syndrome/blood , Respiratory Distress Syndrome/immunology , Respiratory Tract Infections/blood , Respiratory Tract Infections/immunology , Respiratory Tract Infections/microbiology , Trachea/microbiology , Virus Diseases/blood , Virus Diseases/immunology , Virus Diseases/microbiology
6.
Dermatol Online J ; 19(9): 19609, 2013 Sep 14.
Article in English | MEDLINE | ID: mdl-24050284

ABSTRACT

Psoriasis is a chronic, auto-inflammatory disease affecting millions of individuals worldwide. In addition to classic cutaneous manifestations, the condition is linked to significant co-morbidities including cardiovascular disease, metabolic syndrome, melanoma and non-melanoma skin cancer, and psychiatric disease. Therefore, more aggressive treatment and multi-disciplinary care is critical. Measures of disease burden (quantified by anatomic location, body surface area (BSA) of involvement, and impact on daily life) assist in determining the severity of disease and have been integral in objective assessment of treatment regimens and new drug therapies. Biologic agents have entered the clinical armamentarium as treatment options for patients with moderate-to-severe psoriasis who have failed traditional systemic therapies. Three of the four FDA-approved biologic agents for psoriasis suppress TNF-α mediated pathways, which are essential for granuloma formation and maintenance, key components of host defenses against intracellular pathogens. Subsequently, the increased use of these agents is accompanied by increased reporting of granulomatous infectious diseases such as tuberculosis, histoplasmosis, nocardia, and nontuberculous mycobacteria. Report of any unusual infection is therefore vitally important in the care of this immune suppressed patient population.


Subject(s)
Immunoglobulin G/adverse effects , Immunosuppressive Agents/adverse effects , Leg Ulcer/microbiology , Mycobacterium Infections, Nontuberculous/etiology , Nontuberculous Mycobacteria/isolation & purification , Psoriasis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Bacterial Typing Techniques , Cyclosporine/administration & dosage , Cyclosporine/therapeutic use , Drug Therapy, Combination , Etanercept , Female , Fishes/microbiology , Humans , Immunocompromised Host , Immunoglobulin G/administration & dosage , Immunoglobulin G/therapeutic use , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Interferon-gamma Release Tests , Leg Ulcer/etiology , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/microbiology , Nontuberculous Mycobacteria/genetics , Porifera/microbiology , Psoriasis/complications , Receptors, Tumor Necrosis Factor/administration & dosage , Receptors, Tumor Necrosis Factor/therapeutic use , Species Specificity , Triamcinolone/administration & dosage , Triamcinolone/therapeutic use , Tuberculin Test , Ustekinumab
SELECTION OF CITATIONS
SEARCH DETAIL